Celon Pharma (CLN)
- Share price (7-session average)
- 15.63 PLN-3.38% w/w
- Market cap
- PLN 1.1B
- 52-week range
- 15.20 – 23.50 PLN
Prices as of November 20, 2026, delayed.
Last updated: Source: ESEF / ESPI / GPW
Price Chart
About Celon Pharma
Celon Pharma is an integrated biopharmaceutical company engaged in development and manufacturing of generic and innovative drugs. The company conducts research in neuropsychiatry and oncology.
This description was generated with the help of AI and may contain inaccuracies. Please verify important information from official sources.
Company Details
Data sourced from GPW and OpenFIGI. Updated periodically — verify with official sources.
News
Zakwalifikowanie do dofinansowania dwóch projektów Celon Pharma S.A. w konkursie ogłoszonym przez Agencję Badań Medycznych [IGEN]
FilingParkiet
Złożenie wniosków o wydanie pozwoleń na dopuszczenie do obrotu produktu leczniczego zawierającego semaglutyd w postaci roztworu do wstrzykiwań (projekt Reduzek, odpowiednik leku Ozempic).
Capital & financingParkiet
Oświadczenie KDPW o dokonaniu asymilacji 55.000 akcji serii C z akcjami Spółki znajdującymi się w obrocie giełdowym
Capital & financingParkiet
Communities
Frequently asked questions
- How much does a Celon Pharma share cost?
- The 7-day average share price of Celon Pharma (CLN) on GPW is 15.63 PLN.
- On which exchange is Celon Pharma listed?
- Celon Pharma is listed on GPW under the ticker CLN, ISIN: PLCLNPH00015.
- Is Celon Pharma stock being shorted?
- Per the KNF short-selling register (as of November 22, 2026), there are no disclosed net short positions in Celon Pharma. KNF discloses positions from 0.5% of share capital, so smaller ones are not visible.
Similar companies — Pharmaceuticals
Explore the market
This information is provided for informational purposes only and does not constitute investment advice or a recommendation. Listings describe companies by the stated criteria and are not an inducement to buy or sell any financial instrument. Verify figures against official sources before making any investment decision.